HPV Vaccine and Breast Cancer Prevention — Cost, Top Hospitals & Success Rates | MyMedicPlus

Human papillomavirus (HPV) is the most common sexually transmitted infection globally, infecting approximately 80% of sexually active adults at some point in their lifetime. The virus comprises over 200 genotypes, of which approximately 40 infect the anogenital tract. Of these, 12–14 genotypes are classified as ‘high-risk’ or oncogenic types associated with malignant transformation. HPV types 16 and 18 together account for approximately 70% of cervical cancers worldwide; high-risk types 31, 33, 45, 52, and 58 account for a further 15–20%.

HPV vaccines represent one of the most significant achievements in cancer prevention in medical history. Three vaccines have been developed and licensed: the bivalent Cervarix (protecting against HPV 16 and 18); the quadrivalent Gardasil (protecting against HPV 6, 11, 16, and 18); and the nonavalent Gardasil 9 (protecting against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58). Gardasil 9 is now the predominant vaccine used globally, having replaced earlier formulations in most national immunisation programmes. Together, the nine strains covered by Gardasil 9 account for approximately 90% of HPV-related cervical cancers and nearly all HPV-related anogenital and oropharyngeal cancers.

A growing and scientifically interesting — but not yet established — body of evidence has emerged suggesting that HPV may play a role in a subset of breast cancers. A 2022 review by Lawson and colleagues published in Frontiers in Oncology summarised studies detecting HPV DNA in approximately 25% of breast tumour specimens, with high-risk types 16 and 18 predominating. The hypothesis is that HPV may act as a co-carcinogen in breast tissue, potentially facilitated by viral DNA integration into the host genome. However, the current scientific consensus — reflected in the positions of the World Health Organization, Cancer Research UK, the American Cancer Society, and National Cancer Institute — is that this association has not been proven to be causal: detecting HPV DNA in breast tissue does not establish that HPV causes breast cancer, and no clinical data yet supports vaccinating against HPV specifically for breast cancer prevention.

This article reviews the established evidence for HPV vaccination in preventing HPV-associated cancers, the current status of the HPV-breast cancer research hypothesis, vaccination schedules, safety data, and the limitations of current evidence.

HPV vaccination has demonstrated high-level efficacy in preventing a wide range of HPV-related diseases and cancers:

Cervical Cancer: Cervical cancer is the most common HPV-associated malignancy, with approximately 660,000 new cases and 350,000 deaths globally in 2022 (WHO data). HPV types 16 and 18 cause approximately 70% of cervical cancers; the additional five types covered by Gardasil 9 (31, 33, 45, 52, 58) cover a further 15–20%. In vaccine-naive individuals (no prior HPV infection), Gardasil 9 prevents virtually 100% (95% CI: 96.7–100%) of high-grade cervical intraepithelial neoplasia (CIN2/3) and cervical adenocarcinoma in situ caused by the nine covered HPV types, as demonstrated in the VIVIANE and FUTURE II pivotal trials. Real-world evidence from Scotland, Australia, Denmark, and England — where vaccination programmes have been running for over 15 years — has documented dramatic reductions in CIN2+ diagnoses and cervical cancer incidence among vaccinated cohorts.

Oropharyngeal Cancer: HPV, primarily type 16, now causes approximately 70% of oropharyngeal squamous cell carcinomas (cancers of the tonsils, base of tongue, and posterior pharynx) in Western countries, surpassing tobacco as the leading cause of oropharyngeal cancer. HPV-positive oropharyngeal cancer has increased dramatically in incidence over the past three decades. While no large RCT has yet demonstrated a direct reduction in oropharyngeal cancer incidence from HPV vaccination (given the long latency from infection to cancer), epidemiological modelling and immunobridging data strongly support vaccination as a preventive strategy.

Anal Cancer: Approximately 90% of anal squamous cell carcinomas are HPV-related, predominantly HPV type 16. HPV vaccination trials have demonstrated 74–78% efficacy against anal HPV infection and associated precancerous lesions (AIN 2/3) in men who have sex with men (MSM), as demonstrated in the MOVER trial and subsequent data. The UK’s MSM vaccination programme specifically targets anal HPV prevention in high-risk populations.

Vulvar, Vaginal, and Penile Cancers: HPV is responsible for approximately 70% of vulvar cancers, 65% of vaginal cancers, and 50% of penile cancers. Gardasil trials demonstrated efficacy against HPV-related vulvar and vaginal intraepithelial neoplasia (VIN 2/3 and VaIN 2/3) of approximately 100% in vaccine-naive women.

Genital Warts: HPV types 6 and 11 (covered by Gardasil 9) cause approximately 90% of ano-genital warts (condylomata acuminata). Real-world data from countries with high Gardasil coverage show dramatic reductions in genital wart diagnoses — Australia documented a 92% reduction in genital wart diagnoses among women under 21 within 4 years of introducing universal vaccination.

The HPV-Breast Cancer Hypothesis: Multiple studies have detected HPV DNA in breast tumour specimens, with detection rates ranging from 0% to 86% depending on methodology, geographic location, and HPV detection technique used. A 2022 systematic review by Lawson et al. reported a mean HPV prevalence of approximately 25% in breast cancer specimens. High-risk types 16 and 18 are most frequently detected. The theoretical mechanism proposed involves HPV-driven genomic instability and deregulation of cell cycle control proteins (p53, Rb). However, to date no prospective study has demonstrated that HPV infection precedes breast cancer development, and several large studies have found no HPV DNA in carefully controlled breast cancer specimens. The International Agency for Research on Cancer (IARC) does not currently classify HPV as a cause of breast cancer.

HPV vaccination recommendations are based on age, prior HPV exposure status, sex, immune status, and national programme eligibility. Vaccination is most effective when given before sexual debut and therefore HPV exposure, but provides benefit to sexually active individuals who have not yet been infected with all covered HPV types.

Routine Primary Vaccination (Ages 9–14/15): Most national immunisation programmes recommend HPV vaccination routinely for adolescents before age 15, typically in school-based programmes at ages 11–13 in the UK and 11–12 in the USA. At these ages, a 2-dose schedule is sufficient to achieve robust immunogenicity (with a minimum 5-month interval between doses). Early adolescent vaccination, before sexual debut, ensures vaccination in a HPV-naive population and maximises protective efficacy.

Catch-Up Vaccination (Ages 15–26): Individuals aged 15–26 who did not complete vaccination during the primary programme are eligible for catch-up vaccination. At ages 15 and above, a 3-dose schedule is recommended (0, 1–2, and 6 months). In the USA, the CDC Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination through age 26 for all individuals.

Shared Decision-Making (Ages 27–45): ACIP and the FDA have approved Gardasil 9 for use in adults aged 27–45 based on the FUTURE III and VIVIANE bridge data, though routine vaccination is not recommended in this age group due to lower overall benefit at the population level (most adults have already been exposed to some HPV types). For individuals in this age range with a low likelihood of prior HPV exposure (e.g., new sexual partner situations) or specific risk factors, vaccination after shared clinical decision-making between the patient and clinician is appropriate.

Immunocompromised Individuals: Individuals with HIV infection, solid organ transplant recipients, and those on immunosuppressive therapy are at higher risk of persistent HPV infection and HPV-related malignancies. The 3-dose schedule is recommended for all immunocompromised individuals regardless of age, and vaccination should be initiated as early as possible in the disease or treatment course.

Men Who Have Sex with Men (MSM): MSM are at significantly higher risk for HPV-related anal cancer, genital warts, and oropharyngeal cancer. In the UK, the MSM vaccination programme offers Gardasil 9 to MSM aged up to 45 years attending sexual health clinics. ACIP recommendations in the USA similarly support vaccination for MSM aged up to 26.

Previously Vaccinated Individuals: Those who received the bivalent Cervarix or quadrivalent Gardasil are not routinely recommended to receive Gardasil 9 for the additional five HPV types; the decision is made on a case-by-case basis. The additional population-level benefit from revaccination with Gardasil 9 in previously vaccinated cohorts is under study.

Three HPV vaccines have been developed, with Gardasil 9 now the dominant vaccine in most national programmes:

Gardasil 9 (Merck/MSD — 9-valent): Covers HPV types 6, 11 (responsible for ~90% of genital warts), and high-risk oncogenic types 16, 18, 31, 33, 45, 52, and 58 (collectively responsible for ~90% of HPV-related cervical cancers, ~90% of HPV-related oropharyngeal cancers, and virtually all HPV-related anogenital cancers). Gardasil 9 is the vaccine of choice in the UK (replacing the quadrivalent Gardasil from September 2012), USA, Australia, Europe, and most high-income countries. It is a recombinant vaccine using HPV L1 virus-like particles (VLPs) — non-infectious synthetic particles that mimic the outer coat of the virus — adjuvanted with Amorphous Aluminium Hydroxyphosphate Sulfate (AAHS).

Cervarix (GSK — 2-valent): Covers HPV types 16 and 18 only. It uses the AS04 adjuvant (aluminium hydroxide plus MPL) which generates a particularly robust immune response; cross-protective efficacy against HPV 31, 33, and 45 has been observed in Cervarix trials (PATRICIA trial, Paavonen et al., Lancet 2009), suggesting some protection beyond the two target types. Cervarix is still used in some national programmes.

Vaccination Schedules: (1) 2-dose schedule: recommended for individuals who begin vaccination before age 15 (Gardasil 9) or age 14 (Cervarix), with doses at 0 and 6 months (minimum 5-month interval). The 2-dose schedule in younger adolescents achieves equivalent or superior immunogenicity to the 3-dose schedule in older adolescents, due to the more robust immune response in younger individuals. (2) 3-dose schedule: required for individuals aged 15 and over at first dose, or of any age who are immunocompromised or have HIV. Doses are given at 0, 1–2 months, and 6 months (Gardasil 9) or 0, 1, and 6 months (Cervarix). (3) Catch-up and opportunistic vaccination: administered through sexual health clinics, GP practices, and pharmacies for eligible individuals outside the school programme.

Route and Site of Administration: All HPV vaccines are administered as a 0.5 mL intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. They should not be injected intravenously or intradermally. Vaccines are refrigerator-stored (2–8°C) and must not be frozen.

Interchangeability: Gardasil 9 and Cervarix are not interchangeable — the vaccination schedule should ideally be completed with the same vaccine type. If the original vaccine is unavailable or unknown, Gardasil 9 is the preferred option for completion of a course due to its broader coverage.

HPV vaccination is among the most efficacious vaccines ever developed, with extraordinary clinical trial data and growing real-world evidence of population-level cancer prevention.

Cervical Cancer Prevention Efficacy: In vaccine-naive women (no prior HPV exposure), Gardasil 9 achieves approximately 99% efficacy against CIN2/3 and cervical adenocarcinoma in situ caused by HPV 16, 18, 31, 33, 45, 52, and 58 (FUTURE II/III trial programme; Joura EA et al., NEJM 2015). Real-world data from Scotland’s vaccination programme demonstrated 87% reduction in CIN3 among women vaccinated at ages 12–13 (compared to 51% at ages 14–16 and 39% at ages 17–18), confirming the critical importance of vaccination before HPV exposure.

World-Leading Results from National Programmes: Australia introduced universal HPV vaccination in 2007 and is on track to be the first country in the world to eliminate cervical cancer as a public health problem (WHO definition: incidence below 4 per 100,000 women-years). Cervical cancer incidence in Australian women born after 1995 — fully vaccinated cohorts — has fallen by over 90%. Scotland has documented an 89% reduction in cervical cancer incidence in women offered vaccination at age 12–13, compared to unvaccinated cohorts.

Genital Wart Elimination: In countries with high Gardasil coverage, near-elimination of genital warts has been achieved in young vaccinated populations. Australia documented a 92% reduction in diagnoses within 4 years of programme introduction.

Oropharyngeal Cancer Prevention: While direct RCT evidence for oropharyngeal cancer prevention is not yet available (given the 15–30 year latency from HPV infection to cancer), epidemiological modelling predicts substantial reductions in HPV-positive oropharyngeal cancer incidence in vaccinated cohorts, consistent with observed reductions in HPV 16 infection prevalence in vaccinated populations.

Herd Immunity: High vaccination coverage reduces population-level HPV transmission, providing indirect protection to unvaccinated individuals — including those who cannot receive the vaccine for medical reasons. Models estimate that vaccination coverage above 70% in adolescents is sufficient to achieve herd immunity for HPV 16 and 18.

Breast Cancer: Unconfirmed Potential Benefit: If future research confirms a causal role for HPV in a subset of breast cancers, then HPV vaccination could provide a previously unrecognised breast cancer prevention benefit. However, this remains a research hypothesis without clinical evidence to support vaccination decisions for breast cancer prevention specifically. Any reduction in breast cancer risk from HPV vaccination should currently be considered a potential future benefit pending definitive research, not an established indication.

HPV vaccines have been among the most extensively post-marketing surveilled vaccines in history, with safety data from over 300 million doses administered worldwide. The overall safety profile is excellent.

Common, Expected Adverse Events: Injection site reactions — pain (84%), redness (25%), and swelling (25%) at the injection site — are the most frequently reported adverse events and are generally mild and self-limiting, resolving within 24–72 hours without treatment. Systemic reactions including headache (12%), fever (6–10%), nausea, and fatigue are reported at similar or lower rates than with other adolescent vaccines (e.g., Td/Tdap).

Vasovagal Syncope (Post-Vaccination Fainting): Post-vaccination syncope (fainting) is not specific to HPV vaccine — it is a recognised phenomenon with any adolescent vaccination and is related to anxiety and the needlestick stimulus rather than the vaccine itself. Standard post-vaccination observation (15 minutes seated or recumbent) is recommended for all HPV vaccine recipients.

Anaphylaxis: Anaphylaxis following HPV vaccination is extremely rare — estimated at 1–2 cases per million doses administered — consistent with anaphylaxis rates for other vaccines. All vaccination sites must have epinephrine available and vaccinators trained in anaphylaxis management.

Safety Signals Extensively Investigated and Not Confirmed: Following the vaccine’s introduction, several potential adverse effects attracted significant media attention and regulatory review, including complex regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS), and premature ovarian insufficiency (POI). Systematic reviews, WHO Global Advisory Committee on Vaccine Safety (GACVS) assessments, and the European Medicines Agency’s independent review have concluded that the available evidence does not support a causal relationship between HPV vaccination and any of these conditions. Rates of these conditions in vaccinated populations are not higher than in the general population.

Autoimmune Conditions: Large epidemiological studies examining rates of autoimmune conditions (including Guillain-Barré syndrome, multiple sclerosis, systemic lupus erythematosus, and inflammatory bowel disease) in vaccinated versus unvaccinated populations have found no increase attributable to HPV vaccination.

Pregnancy: HPV vaccines are not recommended for use during pregnancy due to limited safety data. If vaccination is inadvertently administered during pregnancy, the pregnancy should not be terminated; however, the remaining doses should be deferred until after delivery. No increased rates of adverse pregnancy outcomes, spontaneous abortion, or congenital malformations have been observed in women inadvertently vaccinated in early pregnancy (WHO, Gardasil pregnancy registry data).

VAERS Reporting: Reports to the US Vaccine Adverse Event Reporting System (VAERS) have been reviewed extensively by CDC and FDA. VAERS captures reported events temporally associated with vaccination but cannot establish causation; the signal-detection analyses have not identified any safety concerns beyond those described in the vaccine labels.

HPV vaccination does not eliminate the need for cervical cancer screening. This is one of the most important public health messages regarding the vaccine programme.

Continued Cervical Screening After Vaccination: Even Gardasil 9 — with its 9-valent coverage — does not cover all oncogenic HPV types. Approximately 10% of cervical cancers are caused by HPV types not included in the vaccine. Additionally, vaccination provides no benefit against HPV infections acquired prior to vaccination (it does not clear existing infections or reverse precancerous changes caused by existing infection). Women who were vaccinated at an older age (15+) may have already been exposed to covered HPV types before vaccination. All of these reasons mean that cervical screening (Pap smear with or without HPV co-testing) remains essential for all vaccinated individuals with a cervix, according to national screening guidelines.

UK Cervical Screening Programme: In England, cervical screening is offered every 3 years to women aged 25–49 and every 5 years to women aged 50–64, using primary HPV testing. A positive HPV result triggers cytological assessment. A negative HPV result allows 5-year recall. Vaccinated women follow the same screening pathway as unvaccinated women; the primary HPV test is equally valid in both groups.

USA Cervical Cancer Screening: The American Cancer Society (ACS) and US Preventive Services Task Force (USPSTF) recommend cervical cancer screening beginning at age 21, regardless of HPV vaccination status: cervical cytology (Pap test) alone every 3 years for ages 21–29; cervical cytology plus HPV co-testing (co-test) every 5 years for ages 30–65; or primary HPV testing (preferred) every 5 years for ages 25–65. The option of discontinuing screening at age 65 with a documented history of adequate negative prior screening applies equally to vaccinated and unvaccinated individuals.

HPV Testing After a Positive Screen: A positive HPV 16 or 18 result on primary HPV screening warrants referral to colposcopy without waiting for cytology, given the high relative risk of CIN2+ associated with these genotypes. Other high-risk HPV types positive with negative or low-grade cytology may be managed with repeat co-testing at 12 months.

Monitoring the HPV-Breast Cancer Research Field: Individuals interested in the evolving HPV-breast cancer research should note that this is an active field of scientific investigation and that current evidence does not change clinical management (vaccination schedules or breast cancer screening recommendations). Clinical breast cancer screening guidelines — mammography starting at age 40–50 depending on national programme — are not affected by HPV vaccination status. Follow developments in this area through peer-reviewed publications rather than news media.

The cost of HPV vaccination varies considerably between countries, depending on whether vaccination is funded through national immunisation programmes, private payment, or insurance coverage.

United Kingdom (NHS): HPV vaccination is provided free of charge under the NHS national immunisation programme for all eligible adolescents in school Year 8 (ages 12–13) in England, Scotland, Wales, and Northern Ireland. Catch-up vaccination for those who missed the school programme is also provided free on the NHS through the age of 25. MSM up to age 45 can receive free vaccination at sexual health clinics. Private HPV vaccination outside these programmes costs approximately £150–£500 for a full 2- or 3-dose course.

United States: The Vaccines for Children (VFC) programme provides free HPV vaccination for eligible children aged up to 18 years (Medicaid-eligible, uninsured, underinsured, or American Indian/Alaska Native). For adults and those purchasing privately, the list price of Gardasil 9 is approximately $250 per dose (USD), making a 3-dose series approximately $750. Most private health insurance plans are required under the Affordable Care Act (ACA) to cover ACIP-recommended vaccines, including HPV vaccination for ages 9–26, without cost-sharing. For ages 27–45, coverage varies by insurer.

Australia: Australia provides free HPV vaccination through the National Immunisation Program (NIP) for all adolescents in school Year 7 (ages 12–13), with catch-up available through to age 19. Australia was an early adopter of a gender-neutral (boys and girls) vaccination programme in 2013.

Low- and Middle-Income Countries: Vaccine cost remains a significant barrier to HPV vaccination in many LMICs. Gavi, the Vaccine Alliance, supports HPV vaccine supply to eligible low-income countries through the COVAX-equivalent HPV programme, at a substantially reduced cost per dose. The WHO 90-70-90 targets for cervical cancer elimination (90% of girls vaccinated by age 15; 70% screened twice by age 35 and 45; 90% with invasive cervical cancer treated appropriately) cannot be achieved without affordable HPV vaccine access in LMICs, where the majority of cervical cancer deaths occur.

India: India introduced the domestic HPV vaccine Cervavac (Serum Institute of India, a quadrivalent vaccine) in 2022, with a list price approximately 80% lower than imported vaccines. The Indian government included Cervavac in the Universal Immunisation Programme (UIP) for girls aged 9–14 from 2023. Private Gardasil 9 vaccination costs approximately INR 4,500–6,500 per dose (USD $55–$80) at private clinics.

Cost-Effectiveness Evidence: HPV vaccination is one of the most cost-effective preventive health interventions available. UK cost-effectiveness analyses consistently demonstrate an incremental cost-effectiveness ratio (ICER) well below the NICE willingness-to-pay threshold of £30,000 per QALY gained, primarily because of the large future healthcare costs averted through cervical cancer and CIN treatment prevention.

HPV vaccination works in conjunction with — not instead of — cervical cancer screening. The following complementary and alternative approaches address different aspects of HPV-related cancer prevention:

Cervical Cancer Screening Alone: For unvaccinated women or those vaccinated at older ages, regular cervical cancer screening (Pap smear, liquid-based cytology, primary HPV testing, or co-testing) remains the primary cervical cancer prevention strategy. Screening detects precancerous lesions (CIN 1, 2, 3) before they progress to invasive cancer, enabling treatment with loop excision (LLETZ/LEEP), cold coagulation, cryotherapy, or cervical cone biopsy. Screening programmes have dramatically reduced cervical cancer mortality in countries with high screening participation, but require participation over decades and involve significant NHS and patient burden — highlighting the complementary importance of vaccination.

HPV Testing and Colposcopy: Primary HPV testing (as used in the current England cervical screening programme) is more sensitive than cytology for detecting high-grade CIN. Women who test HPV-positive undergo reflex cytology, and if abnormal cytology or HPV 16/18 positivity is confirmed, referral to colposcopy — a specialist examination of the cervix using a magnifying instrument — with targeted biopsy allows precise histological diagnosis and guided treatment.

Screening for HPV-Related Cancers Outside the Cervix: No population-level screening programmes exist for HPV-related anal, oropharyngeal, vulvar, vaginal, or penile cancers; however, high-risk individuals — particularly MSM, people living with HIV, and immunosuppressed individuals — may benefit from annual anal cytology or high-resolution anoscopy (HRA) in specialist centres for anal cancer detection.

Lifestyle Measures: While no lifestyle modification can replace the protection of HPV vaccination and screening, reducing the number of sexual partners and consistent condom use reduce (but do not eliminate) the risk of HPV transmission. Condoms do not cover all HPV-exposed skin surfaces in the anogenital region and therefore are not fully protective, but do reduce transmission risk.

Regarding Breast Cancer Screening: Given that the HPV-breast cancer link remains unproven, there are currently no alternative or complementary strategies related to HPV for breast cancer prevention. Established breast cancer risk reduction strategies include mammographic screening, risk-reducing surgery (prophylactic mastectomy) in high-risk BRCA1/2 carriers, and chemoprevention (tamoxifen, anastrozole) in high-risk women. These are independent of HPV vaccination status and remain the clinical standard of care for breast cancer prevention and early detection.